**Supplemental Digital Content 1**

**Survey Responses: Items on the CONSORT and STROBE Statements Requiring an Extension for Simulation-based Research**

|  |  |  |  |
| --- | --- | --- | --- |
| **Checklist Item** | **CONSORT Description1** | **STROBE Description2** | **Respondents, n (%) indicating extension required\*** |
| **Title and abstract** | 1a: Identification as a randomized trial in the title  1b: Structured summary of trial design, methods, results, and conclusions | 1a: Indicate the study’s design with a commonly used term in the title or the abstract.  1b: Provide in the abstract an informative and balanced summary of what was done and what was found. | 17/57 (30%) |
| **Introduction** |  |  |  |
| Background/rationale | 2a: Scientific background and explanation of rationale  2b: Specific objectives or hypotheses | 2:Explain the scientific background and rationale for the investigation being reported. | 15/53 (28%) |
| Objectives | N/A | 3:State specific objectives, including any pre-specified hypotheses. | 11/52 (21%) |
| **Methods** |  |  |  |
| Trial Design / Study Design | 3a: Description of trial design (such as parallel, factorial) including allocation ratio  3b: Important changes to methods after trial commencement (such as eligibility criteria), with reasons | 4:Present key elements of study design early in the paper. | 18/52(35%) |
| Setting | N/A | 5:Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data  collection. | 24/51 (47%) |
| **Checklist Item** | **CONSORT Description** | **STROBE Description2** | **Respondents, n (%) indicating extension required\*** |
| Participants | 4a: Eligibility criteria for participants  4b: Settings and locations where the data were collected | 6a: Cohort study: Give the eligibility criteria, and the sources and methods of selection of participants. Describe  methods of follow-up.  Case–control study: Give the eligibility criteria, and the sources and methods of case ascertainment and control  selection. Give the rationale for the choice of cases and controls.  Cross-sectional study: Give the eligibility criteria, and the sources and methods of selection of participants.  6b: Cohort study: For matched studies, give matching criteria and number of exposed and unexposed.  Case–control study: For matched studies, give matching criteria and the number of controls per case. | 17/51 (33%) |
| Interventions | 5: The interventions for each group with sufficient details to allow for replication, including how and when they were actually administered | N/A | 27/46 (59%) |
| Variables | N/A | 7: Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria,  if applicable. | 16/47 (34%) |
| Data sources / measurement | N/A | 8: For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe  comparability of assessment methods if there is more than one group | 23/48 (48%) |
| **Checklist Item** | **CONSORT Description** | **STROBE Description2** | **Respondents, n (%) indicating extension required\*** |
| Outcomes | 6a: Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed  6b: Any changes to trial outcomes after the trial commenced, with reasons | N/A | 7/45 (16%) |
| Bias | N/A | 9: Describe any efforts to address potential sources of bias | 7/47 (15%) |
| Sample size / Study size | 7a: How sample size was determined  7b: When applicable, explanation of any interim analyses and stopping guidelines | 10: Explain how the study size was arrived at. | 10/46 (22%) |
| Randomization: Sequence generation | 8a: Method used to generate the random allocation sequence  8b: Type of randomization; details of any restriction (such as blocking and block size) | N/A | 7/46 (15%) |
| Randomization: Allocation concealment mechanism | 9:Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | N/A | 7/47 (15%) |
| Randomization: Implementation | 10: Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | N/A | 7/45 (16%) |
| **Checklist Item** | **CONSORT Description** | **STROBE Description2** | **Respondents, n (%) indicating extension required\*** |
| Blinding (masking) | 11a: If done, who was blinded after assignments to interventions (for example, participants, care providers, those assessing outcomes) and how  11b: If relevant, description of the similarity of interventions | N/A | 13/47 (28%) |
| Quantitative variables | N/A | 11: Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen,  and why. | 5/47 (11%) |
| Statistical Methods | 12a: Statistical methods used to compare groups for primary and secondary outcomes  12b: Methods for additional analyses, such as subgroup analyses and adjusted analyses | 12a: Describe all statistical methods, including those used to control for confounding.  12b: Describe any methods used to examine subgroups and interactions.  12c: Explain how missing data were addressed.  12d: Cohort study: If applicable, explain how loss to follow-up was addressed.  Case–control study: If applicable, explain how matching of cases and controls was addressed.  Cross-sectional study: If applicable, describe analytical methods taking account of sampling strategy.  12e: Describe any sensitivity analyses. | 7/47 (15%) |
| **Checklist Item** | **CONSORT Description** | **STROBE Description2** | **Respondents, n (%) indicating extension required\*** |
| **Results** |  |  |  |
| Participants / Participant flow | 13a: For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome  13b: For each group, losses and exclusions after randomization, together with reasons | 13a: Report the numbers of individuals at each stage of the study—e.g., numbers potentially eligible, examined for  eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed.  13b: Give reasons for nonparticipation at each stage.  13c: Consider use of a flow diagram. | 5/46 (11%) |
| Recruitment | 14a: Dates defining the periods of recruitment and follow-up  14b: Why the trial ended or was stopped | N/A | 8/47 (17%) |
| Baseline data / Descriptive data | 15: A table showing baseline demographic and clinical characteristics of each group | 14a: Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and  potential confounders.  14b: Indicate the number of participants with missing data for each variable of interest.  14c: Cohort study: Summarize follow-up time—e.g., average and total amount. | 10/47 (21%) |
| Numbers analyzed | 16: For each group, number of participants (denominator) included in each analysis and whether analysis was by original assigned groups | N/A | 5/46 (11%) |
| **Checklist Item** | **CONSORT Description** | **STROBE Description2** | **Respondents, n (%) indicating extension required\*** |
| Outcomes and estimation / Outcome data | 17a: For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)  17b: For binary outcomes, presentation of both absolute and relative effect sizes is recommended | 15: Cohort study: Report numbers of outcome events or summary measures over time.  Case–control study: Report numbers in each exposure category or summary measures of exposure.  Cross-sectional study: Report numbers of outcome events or summary measures. | 6/46 (13%) |
| Main results | N/A | 16a: Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for and why they were included.  16b: Report category boundaries when continuous variables were categorized.  16c: If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period. | 9/45 (20%) |
| Ancillary analyses / Other analyses | 18: Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | 17: Report other analyses done—e.g., analyses of subgroups and interactions and sensitivity analyses. | 4/46 (9%) |
| Adverse Events | 19: All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) | N/A | 3/46 (7%) |
| **Discussion** |  |  |  |
| Key results | N/A | 18: Summarize key results with reference to study objectives. | 3/46 (7%) |
| **Checklist Item** | **CONSORT Description** | **STROBE Description2** | **Respondents, n (%) indicating extension required\*** |
| Limitations | 20: Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 19: Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and  magnitude of any potential bias. | 7/46 (15%) |
| Generalizability | 21:Generalizability (external validity) of the trial findings | 21: Discuss the generalizability (external validity) of the study results. | 4/46 (9%) |
| Interpretation | 22:Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 20: Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from  similar studies, and other relevant evidence. | 4/46 (9%) |
| **Other Information** |  |  |  |
| Registration | 23: Registration number and name of trial registry | N/A | 1/46 (2%) |
| Protocol | 24: Where the full trial protocol can be accessed, if available | N/A | 1/46 (2%) |
| Funding | 25: Sources of funding and other support (such as supply of drugs), role of funders | 22: Give the source of funding and the role of the funders for the present study and, if applicable, for the original study  on which the present article is based. | 7/46 (15%) |

\*denominator represents number of respondents for the question

**References**

1. Moher D, Hopewell S, Schulz KF et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010; 340:c869.
2. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al., for the STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med*. 2007; 4:e297